1. What are Canadian primary care physicians prescribing for the treatment of gonorrhea?
- Author
-
J Seto, Margaret Gale-Rowe, S Ha, J Wu, and L Pogany
- Subjects
education.field_of_study ,medicine.medical_specialty ,030505 public health ,Chlamydia ,business.industry ,Research ,Incidence (epidemiology) ,Public health ,Population ,Gonorrhea ,General Medicine ,Partner notification ,Azithromycin ,medicine.disease ,Men who have sex with men ,03 medical and health sciences ,0302 clinical medicine ,Family medicine ,medicine ,030212 general & internal medicine ,0305 other medical science ,education ,business ,medicine.drug - Abstract
Background Cases of Neisseria gonorrhea are on the rise in Canada, which-if undetected or undertreated-can lead to morbidity and infertility. In addition, the number of antimicrobial resistant strains is also increasing creating the risk that N. gonorrhea may become untreatable. In 2013, the Public Health Agency of Canada (PHAC) released Canadian recommendations for the management and treatment of gonorrhea that identified the need for combination therapy to address and minimize antimicrobial resistance. However, the level of awareness and uptake of these guidelines is not well-known. Objectives To assess primary care physicians' prescribing practices for the management and treatment of gonorrhea. Methods After validity testing, two online cross-sectional surveys were conducted with a convenience sample of Canadian physicians. Physicians answered true/false statements and open-ended questions relating to three clinical scenarios: 1) suspected anogenital infection drawing from a population of men who have sex with men (MSM); 2) suspected anogenital infection drawing from a non-MSM population; and, 3) suspected pharyngeal infection drawing from any population. Frequencies of responses were calculated for the statements. Open-ended responses were recoded into treatment categories and frequencies were calculated for each scenario. Results A total of 625 physicians completed the survey. Most physicians (60%-95%) accurately identified knowledge statements regarding pharmaceutical management, partner notification and public health reporting. For all clinical scenarios, 30%-35% of physicians did not provide any treatment information, approximately 30% indicated treating with cephalosporin monotherapy, 20%-25% indicated they would prescribe a cephalosporin and azithromycin and a minority of physicians identified other treatment options. When physicians were asked about the purpose of the second antibiotic, azithromycin, 49% indicated it was to provide presumptive treatment for gonorrhea and chlamydia. Forty-one percent indicated it was to provide presumptive treatment for chlamydia only. Conclusion This convenience sample suggests that although knowledge of pharmaceutical management, partner notification, and public health reporting is high, the use of combination therapy to deter the development of antimicrobial resistant gonorrhea may not be widespread among primary care physicians. In light of both the growing incidence of N. gonorrhea and the rising rates of antimicrobial resistance in Canada, consideration on how to improve awareness and update of best prescribing practices in primary care may be indicated.
- Published
- 2017
- Full Text
- View/download PDF